PHM - PHM プルトグル―プ ()


   IAG, PharmaMar, Naturgy, Mapfre...: Zonas de control  2021/06/01 09:07:00 Spain
   Análisis de Merlin Properties, Colonial, ArcelorMittal, PharmaMar, Indra y más...  2021/05/31 06:28:00 Spain
   PulteGroup’s Built to Honor Program Awards Mortgage-Free Home to United States Marine Corps Veteran in Dallas  2021/05/27 12:00:00 Business Insider Markets
In a special dedication event, United States Marine Corps Sergeant Patrick Murray received the keys to his new mortgage-free Pulte Home in the Somerset community in Mansfield, Texas. The home was donated by PulteGroup’s…
   J.M. Smucker viewed cautiously by Morgan Stanley ahead of earnings  2021/05/27 11:49:48 Seeking Alpha
   Investment Grade: Looking Past A Solid Earnings Season  2021/05/27 11:46:00 Seeking Alpha
   PharmaMar baja un 0,4 % tras confirmarse el pago de 5,6 millones en impuestos  2021/05/17 17:16:00 Spain
   PharmaMar cae 2,69 % al tener que pagar 5,6 millones de Impuesto Sociedades  2021/05/17 09:06:00 Spain
   PharmaMar tendrá que abonar 5,6 millones impuesto Sociedades de 2010 a 2012  2021/05/17 08:12:00 Spain
   Jon Najarian Sees Unusual Options Activity In PulteGroup And Las Vegas Sands  2021/05/13 20:27:08 Benzinga
Jon Najarian spoke on CNBC's "Fast Money Halftime Report" about unusually high options activity in PulteGroup, Inc. (NYSE: PHM ) and Las Vegas Sands Corp. (NYSE: LVS ). Traders were buying the July … Full story available on
   PharmaMar baja un 1,6 % en bolsa tras presentar resultados  2021/05/05 16:36:00 Spain
   For Jazz Pharmaceuticals, Failure Is The New Winning  2021/04/05 13:48:29 ValueWalk
In late June, Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) began to market a drug aimed at treating people whose metastatic small cell lung cancer has not responded to an initial round of chemotherapy. Q4 2020 hedge fund letters, conferences and more The drug, lurbinectedin, was developed by Madrid-based PharmaMar S.A., which in December 2019 signed a licensing […] The post For Jazz Pharmaceuticals, Failure Is The New Winning appeared first on ValueWalk .
   PharmaMar ejecuta plan de entrega gratuita de acciones de 826.809 euros  2021/03/22 19:37:00 Spain
   PharmaMar reparte 8.026 acciones gratis entre sus empleados  2021/03/22 18:58:47 El Pais Cinco Dias
   PharmaMar es el mejor en el Ibex 35 pero reduce su ventaja  2021/03/16 07:10:00 Estrategias de inversión
Pharmamar es el mejor valor del Ibex 35 en lo que llevamos de año. Sin embargo, se aleja de los máximos del año a pesar de las buenas recomendaciones sobre Pharmamar
   Multiple Myeloma Drugs Market Trends Show Rapid Growth by 2021-2026 | Amgen, J & J, Celgene, Takeda, Novartis, Daiichi Sankyo, Merck, AB Science, Teva, PharmaMar  2021/03/05 16:38:37 OpenPR
The global Multiple Myeloma Drugs market size is projected to grow from 2021 to 2026. The demand for Multiple Myeloma Drugs can be attributed to patient benefits, growth of the manufacturing sector, increasing production and growing capacity in healthcare industry,